<html xmlns:v="urn:schemas-microsoft-com:vml"
      xmlns:o="urn:schemas-microsoft-com:office:office"
      xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 9">
<meta name=Originator content="Microsoft Word 9">
<link rel=File-List href="./Page3_files/filelist.xml">
<link rel=Edit-Time-Data href="./Page3_files/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title> </title>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>jennifer</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>jennifer</o:LastAuthor>
  <o:Revision>5</o:Revision>
  <o:TotalTime>65</o:TotalTime>
  <o:Created>2004-04-30T13:00:00Z</o:Created>
  <o:LastSaved>2004-05-04T09:46:00Z</o:LastSaved>
  <o:Pages>2</o:Pages>
  <o:Words>463</o:Words>
  <o:Characters>2641</o:Characters>
  <o:Company>EMBL-EBI</o:Company>
  <o:Lines>22</o:Lines>
  <o:Paragraphs>5</o:Paragraphs>
  <o:CharactersWithSpaces>3243</o:CharactersWithSpaces>
  <o:Version>9.4402</o:Version>
 </o:DocumentProperties>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:Zoom>150</w:Zoom>
  <w:DrawingGridHorizontalSpacing>6 pt</w:DrawingGridHorizontalSpacing>
  <w:DisplayHorizontalDrawingGridEvery>2</w:DisplayHorizontalDrawingGridEvery>
  <w:DisplayVerticalDrawingGridEvery>2</w:DisplayVerticalDrawingGridEvery>
 </w:WordDocument>
</xml><![endif]-->
<style>
<!--
 /* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
h1
	{mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:16.0pt;
	font-family:Arial;
	mso-font-kerning:16.0pt;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;
	text-underline:single;}
@page Section1
	{size:595.3pt 841.9pt;
	margin:72.0pt 89.85pt 72.0pt 89.85pt;
	mso-header-margin:35.45pt;
	mso-footer-margin:35.45pt;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
-->
</style>
<!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="1027"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=EN-GB link=blue vlink=purple style='tab-interval:36.0pt'>

<div class=Section1>

<p class=MsoNormal><a href="http://www.ebi.ac.uk/interpro/"
title="To the InterPro database"><span style='text-decoration:none;text-underline:
none'><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:113.25pt;
 height:36.75pt'>
 <v:imagedata src="./Page3_files/image001.jpg" o:title="InterPro_logo"/>
</v:shape><![endif]--><![if !vml]><img border=0 width=151 height=49
src="./Page3_files/image001.jpg" v:shapes="_x0000_i1025"><![endif]></span></a><b><span
style='font-size:28.0pt;mso-bidi-font-size:16.0pt;font-family:Arial;color:navy;
mso-font-kerning:16.0pt'><span style="mso-spacerun: yes"> </span><o:p></o:p></span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span
style='font-size:28.0pt;mso-bidi-font-size:16.0pt;font-family:Arial;color:navy;
mso-font-kerning:16.0pt'>Serpins:<span style="mso-spacerun: yes">  </span></span></b><b><span
style='font-size:28.0pt;mso-bidi-font-size:16.0pt;font-family:Symbol;
mso-bidi-font-family:Arial;color:navy;mso-font-kerning:16.0pt'>a</span></b><b><span
style='font-size:28.0pt;mso-bidi-font-size:16.0pt;font-family:Arial;color:navy;
mso-font-kerning:16.0pt'>1-antitrypsin</span></b></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h1><span style='color:navy'>The suicide pact<o:p></o:p></span></h1>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><span style='mso-tab-count:1'>            </span>Serpins,
nicknamed suicide inhibitors, have developed a unique means of blocking
protease activity.<span style="mso-spacerun: yes">  </span>They employ a
mechanism that covalently traps their targets by undergoing an irreversible
conformational change, effectively destroying both the protease and themselves
into the bargain.<span style="mso-spacerun: yes">  </span></p>

<p class=MsoNormal><span style='mso-tab-count:1'>            </span><span
style='font-family:Symbol'>a</span>1-Antitrypsin contains an exposed reactive
centre loop (RCL) that projects from the body of the protein, acting as ‘bait’
for the protease to attack.<span style="mso-spacerun: yes">  </span>Once the
protease binds the serpin and cleaves the RCL, the RCL undergoes a large
conformational change, resulting in the insertion of the RCL within the
interior of the serpin protein, thereby trapping the covalently bound
protease.<span style="mso-spacerun: yes">  </span>The energy to drive this
rearrangement comes from within the serpin itself.<span style="mso-spacerun:
yes">  </span>While most proteins fold into their most stable state, the native
conformation of <span style='font-family:Symbol'>a</span>1-antitrypsin is said
to be ‘metastable’, or stressed.<span style="mso-spacerun: yes">  </span>The
binding of the target protease triggers the conversion of the serpin to its
most stable, or relaxed, state.<span style="mso-spacerun: yes">  </span>In this
way, the serpin is acting as a kinetic trap, much in the same way as a
mousetrap works: the molecule is under conformational constraint causing it to
snap shut upon binding to the target.<span style="mso-spacerun: yes"> 
</span>Once the serpin is in its most stable state, covalently bound to the
protease, the protease is unable to be released from the ‘jaws’ of the serpin,
locked in a fatal embrace.</p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h1><span style='color:navy'>Serpinopathy, when things go wrong<o:p></o:p></span></h1>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><span style='mso-tab-count:1'>            </span>When
genetic mutations cause a deficiency of one of the many plasma serpins,
diseases can result, which are collectively known as serpinopathies.<span
style="mso-spacerun: yes">  </span>These include diseases such as blood
clotting disorders, emphysema, cirrhosis, and dementia.<span
style="mso-spacerun: yes">  </span>In the case of <span style='font-family:
Symbol'>a</span>1-antitrypsin, a deficiency of this protein can cause liver and
lung disease, as well as a predisposition to certain cancers.<span
style="mso-spacerun: yes">  </span>For example, a mutation in the <span
style='font-family:Symbol'>a</span>1-antitrypsin gene, known as the Z allele
(Glu342Lys), disrupts the structure of the protein, causing <span
style='font-family:Symbol'>a</span>1-antitrypsin polypeptides to link together
to form inactive polymers.<span style="mso-spacerun: yes">  </span>These
polymers accumulate in the liver cells, where most of the <span
style='font-family:Symbol'>a</span>1-antitrypsin is produced.<span
style="mso-spacerun: yes">  </span>This overload of <span style='font-family:
Symbol'>a</span>1-antitrypsin causes neonatal hepatitis, cirrhosis and
hepatocellular carcinoma.<span style="mso-spacerun: yes">  </span>In addition,
the lack of <span style='font-family:Symbol'>a</span>1-antitrypsin in plasma
exposes lung tissue to proteolytic attack by neutrophil elastase, resulting in
excessive degradation of elastin fibres that eventually causes pulmonary
emphysema.<span style="mso-spacerun: yes">  </span>Cigarette smoking can
exasperate emphysema in <span style='font-family:Symbol'>a</span>1-antitrypsin-deficient
patients, because it stimulates neutrophil activation and the release of
neutrophil elastase into the lower respiratory tract.<span style="mso-spacerun:
yes">  </span>The tissue damage caused by the imbalance between neutrophil
elastase and <span style='font-family:Symbol'>a</span>1-antitrypsin can create
a favourable environment for carcinogenesis and tumour progression, hence <span
style='font-family:Symbol'>a</span>1-antitrypsin-deficiency is associated with
an increased risk of liver cancer, bladder cancer, gall bladder cancer,
malignant lymphoma and lung cancer.</p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h1 align=center style='text-align:center'><span style='font-size:18.0pt;
mso-bidi-font-size:16.0pt'>Next:<span style="mso-spacerun: yes">  </span><a
href="Page4.htm" title="Page 4">What InterPro tells us</a><o:p></o:p></span></h1>

<h1 align=center style='text-align:center'><span style='font-size:18.0pt;
mso-bidi-font-size:16.0pt'>Previous:<span style="mso-spacerun: yes">  </span><a
href="Page2.htm" title="Page 2">A balancing act</a><o:p></o:p></span></h1>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><span style='mso-bidi-font-size:13.5pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

</div>

</body>

</html>
